Sign In
Buy EYPT
$12.34
-0.190 (-1.52%)
At Close: Jun 03, 2026
Analysts Are Bullish on These Healthcare Stocks: Momenta Pharma (MNTA), Otonomy (OTIC) - Markets
10:08am, Tuesday, 16'th Jun 2020
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Momenta Pharma
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Global Blood Therapeutics (GBT –
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CytoDyn (CYDY
Analysts Offer Insights on Technology Companies: Iteris (NASDAQ: ITI), Quantum (NASDAQ: QMCO) and OptimizeRx (NASDAQ: OPRX) - Markets
11:36am, Wednesday, 10'th Jun 2020
There’s a lot to be optimistic about in the Technology sector as 3 analysts just weighed in on Iteris (ITI
Large caps deny they're being outgunned by smaller peers in health R&D - Stockhead
09:18am, Wednesday, 10'th Jun 2020
The journey of each individual medical treatment from idea to market requires the involvement of multiple parties big and small. The general consensus seems to be that it takes a big player to get a d
Filled jobs fall 0.1 per cent: Aus shares close 0.1% higher
07:08am, Wednesday, 10'th Jun 2020
10 Jun 2020 - The Australian share market fell at the open, but closed 0.1 per cent up at the end of trade. Filled jobs fell by 0.1 per cent and hours worked by 0.8 per cent between the December and M
What's Opthea eyeing now that it has two successful trials under its belt? - Stockhead
03:44am, Wednesday, 10'th Jun 2020
Having now proven its drug works on two eye diseases, Opthea (ASX:OPT) is looking to future treatment options. The immediate consideration for Opthea is a phase three study on Diabetic Macular Edema
Opthea (ASX:OPT) reports positive trial results: Aus shares 0.5% higher at noon
02:49am, Wednesday, 10'th Jun 2020
10 Jun 2020 - The Australian share market opened lower but is now trading 0.5 per cent up at noon. Opthea (ASX:OPT) has reported positive Phase 2a trial results for its OPT-302 treatment in Diabetic M
Opthea's done it again: Its drug passed its DME clinical trial - Stockhead
12:16am, Wednesday, 10'th Jun 2020
Ten months since Opthea’s (ASX:OPT) drug proved itself against wet-AMD, it’s passed another clinical trial against Diabetic Macular Edema (DME). This morning the company conducted a 144-patient ph
Edited Transcript of EYPT earnings conference call or presentation 6-May-20 12:30pm GMT
02:29am, Tuesday, 09'th Jun 2020
Q1 2020 EyePoint Pharmaceuticals Inc Earnings Call
COVID-19's Timing Could Not Have Been Worse For EyePoint Pharmaceuticals (NASDAQ:EYPT)
09:21am, Tuesday, 02'nd Jun 2020
Before COVID-19, EYPT's revenues were surging quarter over quarter since its Q12019 launch and consensus FY2020 and FY2021 revenue estimates were, per Seeking A
Factbox: China's numerous diplomatic disputes
12:00am, Monday, 01'st Jun 2020
Factbox: China's numerous diplomatic disputes
Should You Buy EyePoint Pharmaceuticals, Inc. (EYPT)?
04:50pm, Wednesday, 27'th May 2020
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).
EyePoint Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
11:00am, Tuesday, 26'th May 2020
WATERTOWN, Mass., May 26, 2020 -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic.
Placenta Growth Factor Pipeline Review, H1 2020: Companies Involved in Therapeutics Development - ResearchAndMarkets.com
12:00am, Thursday, 21'st May 2020
The
